ArticleBioinformation2026
Clinical evaluation of open flap debridement with or without Emdogain® in treating intrabony defects.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periodontitis causes intrabony defects and while open flap debridement (OFD) with EMD and GTR shows promise, the comparative effectiveness of EMD in treating these defects remains underexplored. Open flap debridement (OFD) or access flap surgery is used in conjunction with biological factors such as enamel matrix derivative (EMD) and regenerative techniques involving guided tissue regeneration (GTR) in order to overcome these intrabony defects. In numerous clinical investigations, the application of EMD has demonstrated notable clinical improvements in bone fill clinical attachment gain and pocket depth reduction. Thus, the clinical effectiveness of open flap debridement with and without enamel matrix derivative (EMD) in treating periodontal intrabony defects, further exploring EMD's contribution to clinical outcomes such as bone fill, attachment gain and pocket depth reduction is reported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.